2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Neurotrophic factors for Parkinson’s: insights from a previous workshop
In 2023, Cure Parkinson’s hosted a workshop where leading experts reviewed the potential of neurotrophic factors as a treatment for Parkinson’s disease. A commentary paper summarising the key outcomes was recently published in the Journal of Parkinson’s Disease. What are neurotrophic factors? Neurotrophic factors, or…
Exenatide-PD3 results published
The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately did not meet its primary or secondary endpoints. The full results of the Exenatide-PD3 study have…
How testing the gut could help in the early detection of Parkinson’s
Recent results from a Cure Parkinson’s funded study have provided more evidence for a possible role of the gut in Parkinson’s, as well as identifying new markers to aid in early detection of the condition. There is growing evidence to suggest that the gut may…
Insights on grant applications and research funding from our latest Research Committee interns
At the end of 2023, Cure Parkinson’s set up an internship scheme for PhD students or early post-doctoral researchers to join our Research Committee for a one-year period. This committee is responsible for rigorously reviewing each of our funding applications to ensure they are scientifically robust…
Our latest pre-clinical research project: evaluating the neuroprotective properties of ‘CP-6’
Cure Parkinson’s is excited to announce funding for a new pre-clinical study of ‘CP-6’ for Parkinson’s led by Dr Marco Fazzari and his team at the University of Pittsburgh. CP-6 is a new drug being developed by Creegh Pharmaceuticals. Early lab-based studies have suggested that…